
ZBH Stock Forecast & Price Target
ZBH Analyst Ratings
Bulls say
Zimmer Biomet Holdings is expected to continue its growth acceleration-focused transformation with a solid pipeline of new products and expanded capacity for growth-accelerating and margin-enhancing M&A. Despite some crosscurrents in its latest earnings report, the company showed strong sales, margins, and EPS performance and has the leading share of the orthopedic reconstructive market in multiple regions. If the company can meet its long-term targets, it has potential for enhanced financial returns and multiple expansion in the future.
Bears say
Zimmer Biomet Holdings is facing several challenges that could negatively affect its stock price, including intense competition in the market, inconsistent quarterly performances, potential difficulties in the successful launch of new products, and vulnerability to changes in the US macroeconomic environment. Despite beating revenue and earnings estimates in the first quarter of 2026, underlying margins and performance were less positive, and the earlier-than-expected tariff benefit shift may create challenges for the company in the future. Additionally, although the company has positive ongoing strategic initiatives, such as transitioning to a direct salesforce and launching new products, it is uncertain when these will lead to visible improvements in sales growth, margins, and overall execution. While the recent tariff refund is a positive development, investors should approach Zimmer Biomet with caution due to potential challenges in the future.
This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares